LDE-225 （SMO antagonist），（SMO拮抗劑）；SANT-02/10/50

產品信息

Hedgehog（Hh） 信號通路調節胚胎發育和成體許多組織器官干細胞的自我更新與增殖。然而，那些在正常發育過程中受到Hh信號通路調節的組織器官，在該信號通路異常時常常發 生腫瘤。這些腫瘤包括肝癌、神經膠質瘤、基底細胞癌、橫紋肌肉瘤、胰腺癌、小細胞肺癌、胃癌、結腸癌、前列腺癌、黑色素瘤和多發性骨髓瘤等。

LDE225 (NVP-LDE225):
A potent antagonist of SMO (smoothened). This small molecule compound is a hedgehog pathway inhibitor by directly binding to SMO. This molecule has been developed by the Novartis Pharma for clinical application against hedgehog-dependent cancers.

Purity:
Greater than 99% as determined by LC/MS analysis. LC/MS and/or NMR data available upon request.

Biological Activity:
In a cell-based assay measuring the activation of the Gli-1 reporter gene, this compound gives IC50 of 15-40 nM.

重慶市華雅干細胞技術有限公司